Merck’s Winrevair: A Catalyst for Stock Growth Amid Promising Clinical Developments
In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
The Pharma Letter21h
The week in pharma: action, reaction and insight – week to January 31
Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...